A breakthrough trial has shown promising results for a personalized mRNA cancer vaccine. The vaccine, developed by Moderna and Merck, lowered the risk of melanoma in late-stage trials.

The trial results have had a significant impact on Moderna's shares, which surged 160%.

Further details about the trial and its findings are available, providing more information about this potential development in cancer treatment.